Pharmaceutical stocks often outperform during market downturns because they pay dividends and their products are mostly ...

Trump Orders FDA To Fast-Track US Drug Production As Tariff Threat Looms On Imported Medicines: Cites National Security Concerns President Donald Trump signed an executive order Monday directing ...

AbbVie Inc. (ABBV), headquartered in North Chicago, Illinois, is a biopharmaceutical company discovers, develops, ...

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The latest price target for AbbVie (NYSE:ABBV) was reported by Guggenheim on April 29, 2025. The analyst firm set a price target for $216.00 expecting ABBV to rise to within 12 months (a possible ...

If an investor was to purchase shares of ABBV stock at the current price level of $183.78/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock ...

While tariffs, politics, and pipeline risks loom, the price could be right. AbbVie bounced back after strong fourth-quarter results, but tariff fears and market volatility have sent shares ...

Morgan Stanley analyst Terence Flynn raised the firm’s price target on AbbVie (ABBV) to $241 from $239 and keeps an Overweight rating on the shares. The firm adjusted its large cap pharma and ...

Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. AbbVie is expected to post earnings of $3.11 ...